Novo says CagriSema produced greater weight loss than Lilly rival in a diabetes study
Novo Nordisk reported late-stage results comparing its next-generation obesity candidate with Eli Lilly's treatment in people with type 2 diabetes.
Section
Public health, medicine, wellness, research and healthcare systems.
Novo Nordisk reported late-stage results comparing its next-generation obesity candidate with Eli Lilly's treatment in people with type 2 diabetes.
Proposed rules would restrict sales of foods high in fat, salt or sugar within 50 meters of schools as authorities respond to rising childhood obesity.